港股医药板块直线拉升，恒生生物科技ETF易方达（159105）助力布局产业龙头

Core Viewpoint - The Hong Kong pharmaceutical sector has experienced a significant surge, with the Hang Seng Biotechnology Index rising by 1.5% and the Hang Seng Hong Kong Stock Connect Innovative Drug Index increasing by 2.3% as of 10:30 AM, driven by positive developments in China's biotechnology industry [1] Group 1: Market Performance - The Hang Seng Biotechnology Index and the Hang Seng Hong Kong Stock Connect Innovative Drug Index have shown notable increases, with key stocks such as Xiansheng Pharmaceutical and Kangfang Biotech rising over 5%, and Yuanda Pharmaceutical increasing over 4% [1] - The Nasdaq Biotechnology Index has risen by 13% since the interest rate cut on September 18, 2025, indicating a favorable financing environment for biotechnology companies [1] Group 2: Industry Developments - A record 35 studies from multiple innovative pharmaceutical companies were selected for oral presentations at the ESMO 2025 conference, highlighting the advancements in China's biotechnology sector [1] - Significant collaborations, such as the $11.4 billion partnership between Innovent Biologics and Takeda, reflect global market recognition of the value of Chinese innovative drugs [1] - The recent meeting between the US and Chinese presidents has released positive signals, alleviating some market concerns [1] Group 3: Investment Tools - The Hang Seng Biotechnology Index focuses on leading biotechnology companies in Hong Kong, covering various sub-sectors including biotechnology, pharmaceuticals, and medical devices [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is one of the first ETFs with a 100% focus on innovative drugs, gathering leading innovative pharmaceutical companies in Hong Kong [1] - The E Fund Hang Seng Biotechnology ETF (159105) and the Hang Seng Innovative Drug ETF (159316) track these indices and support T+0 trading, providing diverse investment tools for capturing opportunities in China's biotechnology industry [1]